Citizens JMP raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $95 from $81 and keeps an Outperform rating on the shares. Livmarli delivered another strong quarter of sales as focus is set to shift to the pivotal volixibat data in primary sclerosing cholangitis coming in the second half of 2026, the analyst tells investors in a research note. Mirum remains one of the firm’s favorite names in smid-cap biotech, with the stock up 70% year-to-date and poised for further growth on Livmarli’s commercial growth, path to profitability, and multiple late-stage clinical readouts starting next year in PSC.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals Reports Strong Q3 2025 Growth
- Mirum Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Mirum Pharmaceuticals reports Q3 EPS 5c, consensus (16c)
- Mirum Pharmaceuticals sees FY25 product sales of $500M-$510M, consensus $506.3M
- MIRM Upcoming Earnings Report: What to Expect?